Assoc. Prof. Dr. Jun Xiu sheng – Cancer treatment – Best Researcher Award

Assoc. Prof. Dr. Jun Xiu sheng - Cancer treatment - Best Researcher Award

The First Affiliated Hospital of Dalian Medical University - China 

Author Profile 

SCOPUS 

ORCID 

🎓 Early academic pursuits

Jun Xiu sheng began his academic journey with a strong foundation in clinical medicine. from 2006 to 2011, he pursued a seven-year undergraduate program in clinical medicine at dalian medical university, followed by graduate studies from 2011 to 2013 at the same institution. in 2013, he embarked on a ph.d. in oncology at the graduate school of dalian medical university, sharpening his focus on cancer biology and therapy. his academic path was further enriched through a prestigious exchange scholar program at the medical university of wisconsin, usa, from 2015 to 2016, where he gained international exposure and research insight.

🩺 Professional endeavors

After completing his advanced education, jun xiu sheng joined the first affiliated hospital of dalian medical university. he served as a resident in the department of radiotherapy from 2016 to 2018 and quickly rose through the ranks to become an attending physician (2018–2020). since december 2020, he has held the position of deputy chief physician, where he also serves as an associate professor. his clinical expertise lies in radiation oncology, contributing to the development of novel therapeutic strategies in cancer care. jun xiu sheng’s interest in interdisciplinary approaches, including those inspired by power electronics systems, has made his clinical methods highly adaptive and innovative.

🔬 Contributions and research focus

With a ph.d. in oncology, jun xiu sheng has dedicated his research efforts to understanding the molecular and cellular mechanisms behind tumor resistance and radiotherapy. his recent work explores how melatonin modulates rna splicing in esophageal cancer cells, potentially increasing radiotherapy sensitivity. melatonin, known for its use in treating central nervous system Cancer treatment diseases, has shown promise in suppressing tumor growth. through bioinformatics and rna-seq analysis, jun xiu sheng has investigated the role of variable splicing in radiation resistance, aiming to unlock therapeutic pathways to improve cancer treatment outcomes. integrating ideas from power electronics systems, he also explores regulatory networks in tumor biology.

🌍 Impact and influence

Jun Xiu sheng’s research has not only advanced our understanding of cancer biology but also influenced therapeutic strategies in radiation oncology. by uncovering mechanisms related to rna Cancer treatment variable splicing and the effects of melatonin on tumor cells, he has provided critical insight into resistance pathways. his collaborative roles in national-level projects, including the national natural science foundation of china, have elevated his profile within the academic and medical communities. his interdisciplinary thinking, including applying models from power electronics, offers new paradigms in cancer signal processing and therapy modulation.

📚 Academic cites

Jun Xiu sheng has participated in several major research projects. he contributed to a study on circular rna generation funded by the national natural science foundation of china, and another Cancer treatment on the function of rna variable splicing in tumor radiotherapy resistance. as a principal investigator, he led projects on aspirin-induced rna splicing in lung cancer and on the immune regulation of head and neck squamous cell carcinoma (hnscc). his ongoing research into esophageal cancer immunotherapy and prognosis demonstrates a sustained commitment to scholarly contribution and scientific innovation.

🧬 Legacy and future contributions

Looking forward, jun xiu sheng is committed to deepening his exploration of tumor microenvironments, radiotherapy resistance mechanisms, and immune system interactions in cancer. his current projects funded by liaoning provincial programs and education departments reflect his active role in shaping the future of oncology. he envisions integrating computational and systemic models—akin to feedback loops found in power electronics—to decode complex biological responses in tumors. his legacy will be defined by a blend of rigorous scientific inquiry, clinical excellence, and forward-thinking applications in precision medicine.

Notable Publications 

Title: The role of oncostatin M in esophageal cancer and its potential as a prognostic marker
Author(s): Guangxiang Ding, Xianwei Li, Hongtao Yin, Bing Sun, Junxiu Sheng
Journal: Computers in Biology and Medicine, 2025

Dr. Frédérique Vegran – immuno oncology –  Best Researcher Award

Dr. Frédérique Vegran - immuno oncology -  Best Researcher Award

INSERM - France

Author Profile 

GOOGLE SCHOLAR 

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

🧪 Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications 

  1. Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
    Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
    Journal: The Journal of Clinical Investigation

  2. Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis
    Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
    Journal: Cancer Research

  3. Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
    Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
    Journal: Nature Medicine

  4. Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
    Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
    Journal: PLOS ONE

  5. Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
    Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
    Journal: Nature Immunolog

Prof. Mrinal k ghosh  – Cancer Therapy – Outstanding Scientist Award

Prof. Mrinal k ghosh  - Cancer Therapy - Outstanding Scientist Award

CSIR-Indian Institute of Chemical Biology - India 

Author Profile 

SCOPUS 

🎓 Early academic pursuits

Dr. Mrinal k ghosh earned his b.sc., m.sc., and phd in biochemistry from the university of calcutta, india. his academic journey was characterized by a strong foundation in molecular biology and biochemistry, leading to a prolific research career in cancer biology and inflammatory disorders.

🏢 Professional endeavors

Dr. Ghosh has held various prestigious positions at csir-indian institute of chemical biology, culminating in his current role as chief scientist. his international experience includes post-doctoral research at the cleveland clinic foundation, usa, and academic roles in india, contributing significantly to cancer research and molecular biology.

🔄 Contributions and research focus

Specializing in cancer biology and inflammatory disorders, dr. ghosh has developed groundbreaking research in signal transduction in cancer and stem cells. his work has led to numerous Cancer Therapy publications, patents, and collaborative projects that have advanced the understanding and treatment of cancer.

🏆 Accolades and recognition

His numerous accolades include the bharat vikash award, fellowships from the national academy of science and technology, and the outstanding scientist award. his role as a reviewer for top Cancer Therapy journals and evaluator for national and international projects further highlights his academic stature.

👨‍👩‍👦 Impact and influence

Dr. Ghosh's influence extends beyond his research, impacting policy-making, academic standards, and translational research in india. his leadership roles within csir-iicb and various academic Cancer Therapy committees have shaped the future of scientific research in the country.

🌟 Legacy and future contributions

Dr. Ghosh's legacy is defined by his contributions to cancer biology, his mentorship of future scientists, and his commitment to advancing biomedical research. his ongoing work promises continued innovation and significant contributions to cancer therapy and molecular biology.

Notable Publications 

  • Title: The key vulnerabilities and therapeutic opportunities in the USP7-p53/MDM2 axis in cancer
    Author(s): Gouranga Saha, Mrinal Kanti Ghosh
    Journal: BBA - Molecular Cell Research, 2025

  • Title: Phenolato and alkoxo promoted change in the ligand coordination mode in a four-membered ortho-metalated ruthenium(II) organometallics
    Author(s): Mrinal Kanti Ghosh, Jagannath Chowdhury, Purnananda Garu, Indranil Chakraborty, Swarup Chattopadhyay
    Journal: Polyhedron, 2025

  • Title: Carbon Nanotubes in Cancer Diagnosis and Treatment: Current Trends and Future Perspectives
    Author(s): Sunny Kumar, Aafreen Ansari, Malini Basu, Sabana Begam, Mrinal Kanti Ghosh
    Journal: Advanced Therapeutics, 2025

  • Title: E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities
    Author(s): Sunny Kumar, Malini Basu, Mrinal Kanti Ghosh
    Journal: BBA - Molecular Cell Research, 2024

  • Title: Chromosomal instability (CIN) triggers immune evasion and metastatic potential in cancer through rewired STING signalling
    Author(s): Mrinal Kanti Ghosh, Srija Roy
    Journal: Molecular Biomedicine, 2024